Osteoarthritis
Not a one-week spike. A sustained reduction in chronic OA pain measured over the monitoring window.
TL;DR
SofPulse clinical monitoring data show a 60% reduction in OA pain maintained over the observation period. Unlike immediate post-surgical results, this reflects the chronic-pain population: patients who have been in pain for months or years and who show a sustained response, not a rebound. The honest caveat: this is monitoring data, not a published placebo-controlled RCT for OA specifically.
Clinical monitoring of SofPulse OA patients has shown approximately 60% reduction in reported pain scores maintained over the observation window. This is patient-reported outcome data from a monitoring program — not a blinded placebo-controlled trial specifically in OA. For chronic-pain patients, sustained improvement is a higher bar than acute post-surgical response: the patient has had time to habituate, the placebo effect wanes, and any genuine response represents real relief.
For osteoarthritis specifically, the broader PEMF literature is mixed. Some peer-reviewed systematic reviews find significant benefit; others find inconsistent results. The evidence is strongest in the post-surgical and wound-healing indications where SofPulse's FDA clearance sits. The OA monitoring data presented here is real and consistent with the underlying mechanism — but patients should understand it reflects monitoring data from treated patients, not a blinded RCT in OA. We present it alongside the peer-reviewed evidence, not in place of it.
The chronic-pain OA patient who has cycled through NSAIDs and cortisone and is still in pain has an active inflammatory process that standard care isn't resolving. The calmodulin-NO pathway that tPEMF engages is anti-inflammatory at the cellular level — not just a pain mask. For patients in that situation, addressing the underlying inflammatory process rather than layering another analgesic on top of it is a mechanistically reasonable intervention.
Monitoring data captures real-world outcomes in real patients using the device as prescribed. It captures sustained response — not a lab result in an idealized study cohort. The limitation is absence of a blinded control: patients in a monitoring program know they are using the device, and some portion of measured improvement may reflect the natural trajectory of OA (which can fluctuate) rather than treatment effect. This honest uncertainty is stated plainly here rather than hidden. The 60% figure is the observed outcome; the reader should weight it accordingly — meaningful real-world data, not a placebo-controlled result.
At the point where an OA patient reaches tPEMF, they have typically tried NSAIDs (often contraindicated for continuous use), exhausted their cortisone course (structural concerns after 3–4 injections), and may be on an SNRI or gabapentinoid that is controlling but not resolving the pain. Hyaluronic acid injections are an additional option, though evidence is mixed and coverage is variable. tPEMF adds an anti-inflammatory mechanism with no systemic exposure, no structural risk, no drug interactions, and no injection procedure — a category that no other current standard-of-care intervention occupies.
Sources & references
Related